AGNOS: An 18-month, Open-label, Multi-Center Study to Assess the Effect of fatumumab 20mg SC Monthly in Treatment Naive, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes.
Details
Age
Adult
Type of Study
Treatment
Locations
Brain Imaging Center (BIC)
Outpatient CTRC
University of Colorado Hospital
Principal Investigator
Anna Shah, MD
Study ID
Protocol Number: 21-4783
More information available at ClinicalTrials.gov: NCT05084638
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers